Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Early Colorectal Cancer Detection Employing XNA Technology | 99552
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 1499

Journal of Gastrointestinal & Digestive System received 1499 citations as per Google Scholar report

Journal of Gastrointestinal & Digestive System peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Early colorectal cancer detection employing XNA technology

International Conference on Gastrointestinal Cancer and Therapeutics & 4th World Congress on Digestive & Metabolic Diseases & 26th Annual Congress on Cancer Science and Targeted Therapies

Michael J Powell

DiaCarta Inc., USA

ScientificTracks Abstracts: J Gastrointest Dig Syst

DOI: 10.4172/2161-069X-C8-085

Scientists at DiaCarta have developed an innovative xeno nucleic acid molecular clamp technology, or XNA technology, to address the sensitivity needs for tumor gene mutation and other important gene mutations in liquid biopsy and FFPE samples. XNA technology uses proprietary designed XNA oligomers with modified backbones that hybridize target DNA sequences of interest by Watson-Crick base pairing. When the sequence is a complete match, XNAs hybridize tightly to the DNA target sequences, blocking strand elongation by DNA polymerase in the PCR reaction. However, when a mutation is present in the target sequence, the mismatch leads to instability of the XNA oligomer: DNA duplex, allowing strand elongation by DNA polymerase. As a result, an only target sequence containing mutations is selected for amplification and wild-type sequence, despite being present in much larger DNA amounts/copies, will not be amplified. Since XNA oligomers are not recognized by DNA polymerases, they cannot serve as primers in the subsequent real-time PCR reactions. XNA molecular clamps assays are highly sensitive using nucleic acids obtained from liquid biopsy or tumor tissue biopsy (FFPE) samples. The limit of detection (LOD) can reach as low as 0.1% (7 or 8 copies of mutant DNA) in 5ng of ctDNA, roughly equivalent to 2ml of blood from a patient. Since the presence of high levels of circulating cell-free mutant tumor DNA (ctDNA) and exosome derived nucleic acids have been found to be associated with poor survival in colorectal and other cancers and dynamic monitoring of the level can be used as a predictive factor for cancer treatment.

Michael J Powell is a highly recognized scientific and business leader with more than 25 year’s experience in R&D, technology, and business and corporate development. He has extensive knowledge and experience in the fields of molecular diagnostic assay research and development, qPCR and other nucleic acid amplification technologies, and automated instrumentation platforms. He has published many research papers in leading scientific journals and holds more than 40 patents and patent-pending applications. He received his PhD in medicinal organic chemistry from Loughborough University, Loughborough, UK and also pursued postdoctoral research and a teaching fellowship from the University of Nottingham, Nottingham, UK. He was also a Postdoctoral Industrial Research Fellow at the University of Oxford, UK and was instrumental in developing the amperometric glucose sensing technology that was the basis of Medisense, Inc. which was acquired by Abbott Labs for $950M.

E-mail: [email protected]